BECTON DICKINSON & CO BDX

Healthcare SIC 3841 - Surgical & Medical Instruments & Apparatus NAICS Manufacturing › Miscellaneous Manufacturing › Medical Equipment and Supplies Manufacturing › Surgical and Medical Instrument Manufacturing derived NYSE

Becton, Dickinson and Company (also referred to herein as "BD") was incorporated under the laws of the State of New Jersey in November 1906, as successor to a New York business started in 1897. BD's executive offices are located at 1 Becton Drive, Franklin Lakes, New Jersey 07417-1880, and its telephone number is (201) 847-6800. All references in this Form 10-K to "BD", "the Company", "we", "our" or "us" refer to Becton, Dickinson and Company and its domestic and foreign subsidiaries, unless otherwise indicated by the context.

BD is a global medical technology company engaged in the development, manufacture and sale of a broad range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. We provide customer solutions that are focused on improving medication management and patient safety; supporting infection prevention practices; equipping surgical and interventional procedures; improving drug delivery; aiding anesthesiology care; enhancing the diagnosis of infectious diseases and cancers; and advancing cellular research and applications.

Last close 198.91 2026-10-23
Market cap $54.18B 2026-06-30 share count
52-week range 140.11 - 213.08

Valuation FY2025 figures against the last close

P/S2.5x
P/E34.2x
P/FCF20.3x
EV/EBITDA14.4x
Dividend yield2.2%
Diluted EPS5.82

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $21.84B$20.18B$19.37B$18.87B$19.13B$16.07B$17.29B$15.98B$12.09B$12.48B
Cost of revenue $11.91B$11.05B$11.20B$10.39B$10.50B$9.28B$9.00B$8.71B$6.13B$6.49B
Gross profit $9.93B$9.12B$8.17B$8.48B$8.63B$7.58B$8.29B$7.27B$5.94B$5.99B
R&D $1.26B$1.19B$1.24B$1.26B$1.28B$1.04B$1.06B$1.00B$770.0M$828.0M
SG&A $5.28B$4.86B$4.72B$4.71B$4.72B$4.18B$4.33B$4.02B$2.91B$3.00B
Total operating expenses $19.26B$17.78B$17.26B$16.59B$16.88B$15.16B$15.53B$14.47B$10.57B$11.05B
Operating income $2.58B$2.40B$2.11B$2.28B$2.25B$912.0M$1.76B$1.51B$1.52B$1.43B
Interest expense $613.0M$528.0M$452.0M$398.0M$469.0M$528.0M$639.0M$706.0M$521.0M$388.0M
Pre-tax income $1.88B$2.00B$1.66B$1.78B$1.69B$414.0M$1.18B$1.17B$976.0M$1.07B
Income tax $203.0M$300.0M$132.0M$148.0M$88.0M$62.0M$57.0M$862.0M$124.0M$97.0M
Net income $1.68B$1.71B$1.48B$1.78B$2.09B$874.0M$1.23B$311.0M$1.10B$976.0M
EPS, basic 5.835.884.975.936.922.754.010.624.704.59
EPS, diluted 5.825.864.945.886.852.713.940.604.604.49
Shares, diluted (wtd. avg.) 288.5M291.0M288.4M287.4M292.1M282.4M274.8M264.6M223.6M217.5M

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents $641.0M$1.72B$1.48B$1.16B$2.39B$2.92B$590.0M$1.24B$14.18B$1.54B
Receivables $2.99B$3.03B$2.53B$2.19B$2.35B$2.40B$2.35B$2.32B$1.74B$1.62B
Inventory $3.89B$3.84B$3.27B$3.22B$2.74B$2.74B$2.58B$2.45B$1.82B$1.72B
Total current assets $9.26B$10.47B$8.68B$8.14B$8.84B$8.97B$6.66B$7.41B$18.63B$6.37B
Property, plant and equipment $7.00B$6.82B$6.56B$6.01B$6.00B$5.92B$5.66B$5.38B$4.64B$3.90B
Goodwill $26.61B$26.46B$24.52B$24.62B$23.89B$23.60B$23.38B$23.60B$7.56B$7.42B
Other intangibles $9.39B$10.87B$10.90B$12.26B$12.73B$13.77B————
Total assets $55.33B$57.29B$52.78B$52.93B$53.87B$54.01B$51.77B$53.90B$37.73B$25.59B
Accounts payable $1.97B$1.90B$1.64B$1.70B$1.74B$1.35B$1.09B$1.11B$797.0M$665.0M
Short-term debt $1.56B$2.17B$1.14B$2.18B$500.0M$707.0M$1.31B$2.60B$203.0M$1.00B
Total current liabilities $8.31B$8.96B$6.64B$7.81B$6.63B$5.84B$5.66B$7.22B$3.34B$4.40B
Long-term debt $17.62B$17.94B$14.74B$13.89B$17.11B$17.22B$18.08B$18.89B$18.67B$10.55B
Retained earnings $16.62B$16.14B$15.54B$15.16B$13.83B$12.79B$12.91B$12.60B$13.11B$12.73B
Total equity $25.39B$25.89B$25.80B$25.28B$23.68B$23.77B$21.08B$20.99B$12.95B$7.63B

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating cash flow $3.43B$3.84B$2.99B$2.47B$4.13B$2.94B$3.33B$2.87B$2.55B$2.56B
Depreciation and amortisation $2.46B$2.29B$2.29B$2.23B$2.23B$2.12B$2.25B$1.98B$1.09B$1.11B
Stock-based compensation $258.0M$247.0M$259.0M$233.0M$229.0M$236.0M$261.0M$322.0M$174.0M$196.0M
Capital expenditure $760.0M$725.0M$874.0M$973.0M$1.19B$769.0M$957.0M$895.0M$727.0M$693.0M
Investing cash flow -$818.0M-$5.51B-$716.0M-$3.22B-$1.84B-$1.19B-$741.0M-$15.73B-$883.0M-$669.0M
Financing cash flow -$3.62B$2.09B-$1.96B-$736.0M-$3.31B$22.0M-$3.22B-$58.0M$10.98B-$1.76B
Dividends paid $1.20B$1.10B$1.11B$1.08B$1.05B$1.03B$984.0M$927.0M$677.0M$562.0M
Buybacks $1.00B$500.0M$0$500.0M$1.75B$0$0$0$220.0M$0

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0000010795-25-000099.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. 0 10B 20B 30B Revenue, FY2016: 12.5B Gross profit, FY2016: 6B Net income, FY2016: 976M Revenue, FY2017: 12.1B Gross profit, FY2017: 5.9B Net income, FY2017: 1.1B Revenue, FY2018: 16B Gross profit, FY2018: 7.3B Net income, FY2018: 311M Revenue, FY2019: 17.3B Gross profit, FY2019: 8.3B Net income, FY2019: 1.2B Revenue, FY2020: 16.1B Gross profit, FY2020: 7.6B Net income, FY2020: 874M Revenue, FY2021: 19.1B Gross profit, FY2021: 8.6B Net income, FY2021: 2.1B Revenue, FY2022: 18.9B Gross profit, FY2022: 8.5B Net income, FY2022: 1.8B Revenue, FY2023: 19.4B Gross profit, FY2023: 8.2B Net income, FY2023: 1.5B Revenue, FY2024: 20.2B Gross profit, FY2024: 9.1B Net income, FY2024: 1.7B Revenue, FY2025: 21.8B Gross profit, FY2025: 9.9B Net income, FY2025: 1.7B FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue $12.48B $12.09B $15.98B $17.29B $16.07B $19.13B $18.87B $19.37B $20.18B $21.84B
Gross profit $5.99B $5.94B $7.27B $8.29B $7.58B $8.63B $8.48B $8.17B $9.12B $9.93B
Net income $976.0M $1.10B $311.0M $1.23B $874.0M $2.09B $1.78B $1.48B $1.71B $1.68B

Recent filings and events

  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
  • Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
  • Regulation FD disclosure Item 7.01
  • Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
  • New debt or obligation The company has taken on debt or a comparable obligation. Item 2.03
  • Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
  • Results announced Item 2.02
  • Officer or director change Item 5.02
  • Regulation FD disclosure Item 7.01
  • Charter or fiscal year changed A change to the company's governing documents, or to when its year ends. Item 5.03
  • Officer or director change Item 5.02

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 3841

TickerCompanyMarket capP/ERevenue growth
SYK STRYKER CORP $117.81B 36.6x 11.2%
MMM 3M CO $89.46B 28.9x 1.5%
BSX BOSTON SCIENTIFIC CORP $66.22B 23.6x 19.9%
RMD RESMED INC $36.48B 24.2x 9.9%
DXCM DEXCOM INC $29.41B 37.3x 15.6%
MDLN Medline Inc. $29.20B — 11.5%
WST WEST PHARMACEUTICAL SERVICES INC $27.60B 57.8x 6.3%
SOLV Solventum Corp $14.54B 9.6x 0.9%